| RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA |
Rejected |
- |
4 |
A8081046 |
N/A |
| "(LUMINOUS)Study to observe the effectiveness andsafety of ranibizumab through individualized patienttreatment and associated " |
Completed |
Ranibizumab 10mg/ml (Lucentis) |
4 |
RFB002A2406 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), Prince Sultan Military Medical City (Riyadh) |
| An observational study to evaluate the effectiveness, safty and effect on health-related quality of life of treatment in routine practice (PERFORMS) |
Completed |
Fingolimod |
4 |
CFTY720D-MAX-TH-01 |
King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah) |
| An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE). |
Completed |
Zoledronic acid |
4 |
CZOL446H-MAX-SA-01 |
King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh) |
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care |
Ongoing |
KB195 |
2 |
K020-218 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. |
Terminated |
RO7034067 |
2 |
BP39056 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS |
Terminated |
Ocrelizumab |
3b |
MN39159 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS |
Ongoing |
Emicizumab |
3 |
MO39129 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "Tranexamic acid for the treatment of gastrointestinal hemorrhage: aninternational randomized, double-blind, placebo-controlled trial" |
Completed |
Tranexamic acid |
3 |
ISRCTN11225767 |
Prince Mohammad bin Abdulaziz hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. |
Completed |
DICLOFENAC POTASSIUM |
BE |
42856 |
Saudi Ajal |
